Board of Directors
Chairman of the Board
Principal, Warren Enterprise Associates, Boston
Jeff Warren is engaged in an active law practice, and also consults on management, business strategy and development issues. He is a seasoned corporate finance lawyer and has also been a private equity investor/fund manager, CEO, and director of several companies. He is engaged in several executive management/consulting activities with life science and other technology driven companies.
Warren was previously a partner in several large law firms, among them American Lawyer 100 firms with international offices. He has been admitted to the bar for more than 30 years in Texas, and is also admitted in Arizona, California and Massachusetts. He left the large firm practice to form and act as co-managing partner of Eaglestone Partners I, LLC, the general partner to Eaglestone Investment Partners I, LP, an institutionally financed private equity fund based in Southern California. When Eaglestone was fully invested, Warren established his own law and business consulting practice, and has contracted or been associated to work with several law firms on a project referral and other basis.
Warren often is an invited speaker on entrepreneurship and other business related topics. He earned his undergraduate degree from Purdue University and a Juris Doctor from the University of Houston Law Center, both with honors.
Julie K. Goonewardene
President, KU Center for Technology Commercialization
Julie K. Goonewardene is a recognized leader in technology commercialization, business formation and public/private partnerships. In addition to serving as Associate Vice Chancellor for Innovation and Entrepreneurship at the University of Kansas (KU), she is president of the KU Center for Technology Commercialization and a professor of practice in the KU School of Business. She is responsible for all university-wide commercialization efforts with the intellectual property, company formation, corporate outreach, and foundation research relationship groups reporting to her. Prior to KU, she held various roles at Purdue University; among her primary focus areas was company formation and capital acquisition for start-up companies.
Goonewardene is an experienced entrepreneur herself, having co-founded and served as president and CEO of Cantilever Technologies; president of Strategic Systems Group; and co-founder of Technology Solutions. She is a member of the Board of Trustees for the American Medical Association (AMA) and on the board of the Personalized Medicine Coalition. She is an author and frequent speaker on entrepreneurship and innovation. Goonewardene earned a BS in Management with Honors and a master’s degree in Health Communication from Purdue University.
Deborah J. Neff
Executive Management Advisor
Palo Alto, California-based Deborah J. Neff is a veteran of the life sciences industry, with experience in building market-leading global businesses and product commercialization. Over the last 25 years, Neff has served as worldwide president of BD Biosciences, Inc., a business unit of Becton Dickinson; and president and CEO of Predicant Biosciences, Inc., and Pathwork Diagnostics, Inc. Her work in cancer diagnostics includes establishing a CLIA/CA/NY-certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines.
Neff also serves on the board of Bio-Rad, Inc., and is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation, Inc., which were acquired by Abbott and Pall Corporation respectively. Neff is a member of the Dean’s Leadership Council at the University of California, Davis (UC Davis) College of Biological Sciences. She earned a BS in Physiology from UC Davis, and completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
Daniel Raftery, PhD, MBA
Founder and Chief Scientific Officer
Daniel Raftery is the chief scientific officer and founder of Matrix-Bio, Inc. A nationally recognized expert in the field of metabolomics, he invented the biomarker analysis methodology that forms the core of the company’s technology. He has more than 20 years of experience in nuclear magnetic resonance and mass spectrometry analysis, the gold standards for metabolite biomarker analysis.
Raftery is a Medical Education and Research Endowed Professor in the Department of Anesthesia and Pain Medicine and Director of the Northwest Metabolomics Research Center at the University of Washington in Seattle. He is also a member of one of the world’s leading cancer research centers, the Fred Hutchinson Cancer Research Center in Seattle. Raftery’s work is supported by the National Institutes of Health and U.S. Department of Defense. Prior to joining the University of Washington, Raftery was a Professor of Analytical and Physical Chemistry at Purdue University in West Lafayette, IN, where Matrix-Bio was founded.
A graduate of Harvard College, Raftery earned his PhD from the University of California, Berkeley. He earned his MBA from the University of Chicago. He completed a National Science Foundation postdoctoral fellowship at the University of Pennsylvania. He has received numerous national and international awards and is widely published.
Eric G. Beier, MD, MBA
CEO, Matrix-Bio, Inc.
A former emergency room physician, medical consultant and seasoned entrepreneur, Eric Beier serves as the CEO of Matrix-Bio, Inc. and as a member of the Matrix-Bio Board of Directors representing the Main Street Venture Fund. An active angel investor, Matrix-Bio is his third start-up company. Beier also serves as an advisor to the Paladin Liberator Fund I, LP. He is the Chief Medical Officer of MediGain, a global physician revenue cycle management firm based in Dallas, Texas. Previously, he was president of MedOptima, a physician revenue cycle management, practice management and consulting company he founded in 2005, and as president of Professional Medical Billing, an emergency medicine billing company. Beier served as the product line manager for cardiovascular diagnostics and in the Medical Affairs group at Boehringer Mannheim Corporation, now a part of Roche Diagnostics.
Beier graduated summa cum laude from Hanover College with a BA in Chemistry. He earned his medical degree from the Indiana University School of Medicine and an MBA from the University of Michigan.